Boston Scientific Corporation has announced significant advancements in the use of artificial intelligence $(AI)$ to predict and prevent cardiac emergencies. Their AI technology is transforming healthcare by shifting from reactive to proactive and predictive medicine, enhancing the quality of care through early diagnoses and intervention. The company's HeartLogic™ Heart Failure Diagnostic, the first FDA-approved predictive analytic alert in an implantable device, is helping identify patients at risk for worsening heart failure weeks before symptoms appear. This innovative technology analyzes various physiological biomarkers, enabling the prediction of up to 70% of heart failure cases approximately 34 days in advance, thereby allowing physicians valuable time to intervene and potentially prevent emergencies.